RecruitingPhase 1NCT05942625
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Studyto Evaluate the Safety, Tolerability and Pharmacokinetics of HS-10390 in Healthy Subjects
Sponsor
Hansoh BioMedical R&D Company
Enrollment
84 participants
Start Date
May 23, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
Eligibility
Min Age: 18 YearsMax Age: 45 Years
Inclusion Criteria3
- Healthy male or female subjects between the ages of 18-45 years
- Have no reproductive potential; or agree to use a highly effective method ofcontraception, and refrain from donating sperm or eggs during the study period and forat least 6 months after last dosing
- Have signed the informed consent form approved by the IRB
Exclusion Criteria7
- History or evidence of clinically significant cardiovascular, pulmonary, endocrine,gastrointestinal, psychiatric, neurologic, hematological or metabolic diseases, especiallythose conditions that interfere with absorption, metabolism and/or excretion of the studydrug, determined by the investigator
- Have a clinically significant infection currently or within past 30 days, or have a history ofactive tuberculosis; or have positive screening test for infectious disease, includingtuberculosis, viral hepatitis, AIDS and syphilis
- Have a history of or current allergic disease
- Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol ordrugs of abuse
- Smokers smoked ≥5 cigarettes per day within past 3 months or have a positive test resultfor nicotine
- Clinically significant abnormal physical examination, vital signs, clinical laboratory values,ECGs or imaging tests
- Pregnant or breastfeeding female subjects
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGHS-10390 tablet
Oral administration of specified dose of HS-10390
DRUGPlacebo tablet
Oral administration of matching dose ofplacebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05942625
Related Trials
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
NCT066648141 location
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083251 locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT0650070270 locations
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
NCT072686388 locations
Study of BHV-1400 in IgA Nephropathy
NCT0705468412 locations